01—Abstract
Summary
Summary of the 10-Q filed August 1, 2024. Cited figures are marked; the original filing is the authoritative source.
Biogen Inc. reported a slight increase in total revenue for the three months ended June 30, 2024, reaching $2,464.9 milliona, a 0.4% rise year-over-year.
This was primarily driven by a 2.9%b increase in product revenue, largely from the rare disease segment, which saw a significant boost from SKYCLARYS sales. However, revenue from contract manufacturing, royalty, and other sources declined by 31.7%.
Diluted earnings per share decreased by 1.7% to $4.00c, reflecting higher amortization costs related to the Reata acquisition's intangible assets and a substantial increase in 'Other (income) expense, net,' which more than offset a decrease in R&D and cost of sales. The company also announced the completion of the HI-Bio acquisition for $1.15 billion, funded by existing cash, and the sale of a priority review voucher for $103.0 million, contributing to a substantial increase in cash and cash equivalents to $1.9 billion.
02—Key points
Key Highlights
- Total revenue for Q2 2024 was $2,464.9 million, a 0.4% increase from Q2 2023, driven by product revenue growth.
- Product revenue increased by 2.9% to $1,899.6 million, with the rare disease segment showing strong growth (+21.9%) due to SKYCLARYS, while the Multiple Sclerosis segment saw a 4.9% decline.
- Diluted earnings per share (EPS) decreased by 1.7% to $4.00, impacted by higher amortization expenses and increased 'Other (income) expense, net'.
- Cost of sales decreased by 7.9% and R&D expenses decreased by 12.0%, partly due to cost-reduction measures and portfolio prioritization.
- Cash and cash equivalents significantly increased to $1,908.9 million from $1,049.9 million at the end of 2023, bolstered by operating cash flow and proceeds from asset sales.
- Biogen completed the acquisition of HI-Bio for $1.15 billion, expanding its pipeline in immunology.
- The company sold a priority review voucher for $103.0 million, generating a net gain of $88.6 million.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2024filed August 1, 2024Financial Statements
Q2 FY2024 against Q2 FY2023
| Line item | Q2 FY2024Q2 FY2023 | Change |
|---|---|---|
| Revenue | $2.46B$2.46B | +0.4% |
| Cost of Revenue | $546.00M$592.70M | −7.9% |
| Gross Profit | $1.92B$1.86B | +3.0% |
| SG&A Expenses | $553.80M$548.00M | +1.1% |
| Operating Expenses | $1.77B$1.75B | +1.0% |
| Interest Expense | $61.30M$49.10M | +24.8% |
| Net Income | $583.60M$591.60M | −1.4% |
| EPS (Basic) | $4.01$4.09 | −2.0% |
| EPS (Diluted) | $4.00$4.07 | −1.7% |
| Shares Outstanding (Basic) | 145.60M144.70M | +0.6% |
| Shares Outstanding (Diluted) | 145.90M145.50M | +0.3% |
05—Questions
Frequently Asked Questions
What was the primary driver for the increase in Biogen's total revenue in Q2 2024?
Biogen's total revenue increased by 0.4% to $2,464.9 million in Q2 2024, primarily driven by a 2.9% increase in product revenue. The rare disease segment, boosted by SKYCLARYS sales, was a key contributor to this growth, offsetting a decline in the Multiple Sclerosis segment.
Why did Biogen's earnings per share (EPS) decrease despite revenue growth?
Despite a slight increase in revenue, Biogen's diluted EPS decreased by 1.7% to $4.00. This was mainly due to a significant increase in amortization expenses related to acquired intangible assets from the Reata acquisition, and a substantial rise in 'Other (income) expense, net', which together more than offset the cost savings achieved in R&D and cost of sales.
How did the recent acquisitions and divestitures impact Biogen's financial position?
Biogen completed the acquisition of HI-Bio for $1.15 billion, funded by cash on hand, which is expected to bolster its immunology pipeline. Additionally, the company sold a priority review voucher for $103.0 million, contributing to a substantial increase in its cash and cash equivalents to $1.9 billion as of June 30, 2024. These transactions demonstrate active portfolio management.
What is the outlook for Biogen's Multiple Sclerosis (MS) business?
The MS segment continues to face challenges, with global MS revenue declining by 4.9% in Q2 2024. This is attributed to increased competition, patient transitions to higher efficacy therapies for its interferon products, and competition for TYSABRI. Biogen anticipates a continued decline in MS revenue due to ongoing competition and the introduction of biosimilars.
06—Continue